Anti-diabetic pharmaceuticals market in India is one of the most lucrative diabetes markets in the world. Since India is the second largest diabetic pool in the world after China, the Indian market is characterized by a huge demand for anti-diabetic drugs. It is a highly fragmented market with a large number of foreign and domestic players. The huge increase in the number of diabetes cases, introduction of newer and better drugs, increasing aging population and introduction of diabetes insurance policies is helping the market to grow. The Indian Government, on its part, has introduced some diabetes control programmes. The market is expected to exhibit steady growth over the next few years.
The report begins with the introduction section which offers a brief classification of the different types of diabetes. It then gives a classification of the diabetes market, and then provides a brief description of different classes of anti-diabetic pharmaceuticals. The market overview section provides an insight into the global market and then moves on to the Indian market, highlighting the market size and growth. It also provides a global diabetes map.
An analysis of the drivers explains the factors for growth of the industry including increasing diabetes cases, introduction of newer and better drugs, increasing aging population and increase in health insurance policies. The key challenges include price regulation in the insulin market, competition from use of complementary and alternative medicines and maintainence of a healthy lifestyle to avoid diabetes.
The government initiatives section gives a brief description of the different diabetes programmes undertaken by the Government.
A brief overview of the drug regulations and patents is presented in the next section. It focuses the different stages of clinical trial that a drug must pass through. Drug regulations in India and drugs approved for marketing have been provided. The section also provides a list of important patent approvals for anti-diabetic drugs.
The competition section gives overview of pharmaceutical companies in the country operating in the anti diabetic pharmaceutical and insulin segments along with segmentation of players in respect to production of oral drugs and insulin. Thereafter, the report highlights the features of the major players operating in the market in detail. It includes elaborate profile of the major players in the market along with their financial analysis. Porters Five Forces Analysis has been incorporated for a brief but effective understanding of the market scenario.
The strategic recommendations section focuses on some effective strategic decisions which can be taken up by companies to increase their market shares.
Interested in this report?
Get your sample now!
Page 1: Executive summary
Introduction
Page 2: Types of diabetes
Page 3: Classification of the diabetes market
Page 4: Classes of anti-diabetic drugs
Market Overview
Page 5: Global Anti-Diabetic Pharmaceuticals Market - Overview, Size & Growth (Value: 2010-15e),
Page 6: Indian Anti-Diabetic Pharmaceuticals Market - Overview, Size & Growth (Value: 2010-2015e), Growth in Therapeutic segments
Page 7: Global Diabetes map
Drivers & Challenges
Page 8: Summary
Page 9-12: Drivers
Page13-14: Challenges
Government initiatives
Page 15: Government programmes
Market Value Chain, Regulation and Patents
Page 16: Pharmaceutical value chain
Page17: Phases of clinical trials
Page18-19: Drug regulations
Page 20: Regulatory framework
Page 21: List of patent approvals
Competition
Page 22: Competition overview
Page 23: Segmentation of players
Page 24: Market Competition - Porter'sFive Forces Analysis
Page 25: Summary- Major public players
Page 26-61: Major Public Players
Aventis Pharma Limited
Biocon Limited
Cipla Limited
Dr. Reddy's Laboratories Limited
GlaxoSmithKline Pharmaceuticals Limited
Merck Limited
Panacea Biotec Limited
Ranbaxy Laboratories Limited
Strides Arcolab Limited
Sun Pharmaceutical Industries Limited
Torrent Pharmaceuticals Limited
Wockhardt Limited
Page 62: Summary - Major Private Players
Page 63-74: Major Private Players
Bristol-Myers Squibb India Private Limited
Eli Lilly and Company (India) Private Limited
Novo Nordisk India Private Limited
Takeda Pharmaceuticals India Private Limited
Page 75: Recent Developments
Strategic Recommendation
Page 76: Strategic Recommendations
List of Charts & Figures
Market Overview
1. Anti Diabetic Pharmaceutical Market- Global Market Size and Growth (Value wise 2010 - 2015e)
2. Market Segmentation- Global (Percentage wise 2010 & 2015e)
3. Anti Diabetic Pharmaceutical Market - India Market Size and Growth (Value-Wise, 2010 - 2015e)
4. Growth in therapeutic segments (Percentage wise 2010)
5. Market Segmentation- India (Percentage wise 2010 & 2015e)
Drivers and Challenges
6. Increase in diabetic patients - India (Value wise 2010 - 2030e)
7. Demography- People >60 years in India (Value- Wise 2005 - 2020e)
Competition
8. Bubble chart: Competitive summary of major public and private companies
Except Takeda Pharmaceuticals India Private Limited
9. Financial Snapshot
10. Key Business segments (only Public Players)
11. Key Geographic segments (only Public Players)
Except GlaxoSmithKline Pharmaceuticals Limited
List of Tables
Market Value Chain, Regulation and Patent
1. Tabular representation of drugs approved in recent past (2008- 2010)
2. Tabular representation of regulatory framework of Indian Pharmaceutical Industry
3. Tabular representation of USFDA patent approvals
Competition
4. Segmentation of pharmaceutical companies
5. Company profiles (All companies)
a. Company information
b. Products and services
c. Key people
d. Key Financial Performance Indicators
e. Key Ratios
f. Business Highlights
Appendix
6. Ratio Calculations
Market Overview
1. Anti Diabetic Pharmaceutical Market- Global Market Size and Growth (Value wise 2010 - 2015e)
2. Market Segmentation- Global (Percentage wise 2010 & 2015e)
3. Anti Diabetic Pharmaceutical Market - India Market Size and Growth (Value-Wise, 2010 - 2015e)
4. Growth in therapeutic segments (Percentage wise 2010)
5. Market Segmentation- India (Percentage wise 2010 & 2015e)
Drivers and Challenges
6. Increase in diabetic patients - India (Value wise 2010 - 2030e)
7. Demography- People >60 years in India (Value- Wise 2005 - 2020e)
Competition
8. Bubble chart: Competitive summary of major public and private companies
Except Takeda Pharmaceuticals India Private Limited
9. Financial Snapshot
10. Key Business segments (only Public Players)
11. Key Geographic segments (only Public Players)
Except GlaxoSmithKline Pharmaceuticals Limited
Market Value Chain, Regulation and Patent
1. Tabular representation of drugs approved in recent past (2008- 2010)
2. Tabular representation of regulatory framework of Indian Pharmaceutical Industry
3. Tabular representation of USFDA patent approvals
Competition
4. Segmentation of pharmaceutical companies
5. Company profiles (All companies)
a. Company information
b. Products and services
c. Key people
d. Key Financial Performance Indicators
e. Key Ratios
f. Business Highlights
Appendix
6. Ratio Calculations
